A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

170 Appendix 8 TABLE 84 Chiou et al., 2004 170 (cont’d) Modelling summary A decision tree was developed in Data 4.0 (TreeAge software) to compare the costs and outcomes of a hypothetical cohort of patients. The time-horizon was 1 year, and effectiveness was measured at 6 and 12 months. The structure of the model is flexible, allowing for data that may be available over a longer follow-up period. If effectiveness data were not available at 12 months, 6- and 12-month effectiveness data were assumed to be equivalent. Within the model 16 health states were used: these were the product of the severity of SAE and the ACR response criteria, e.g. a patient could have no ACR, ACR20, ACR50 or ACR70 and could be experiencing no SAE, mild SAEs, moderate SAEs or severe SAEs Outcome measures used in Effectiveness was measured in QALYs. It was assumed that patients would live with one of economic evaluations the 16 health states at any given time. Preference weights for each health state, used to calculate the QALYs, were measured using a VAS (HAQ) obtained from a survey of 748 patients with RA Direction of result with NE quadrant. Monotherapies: etanercept NE quadrant, US$13,387 per QALY. Adalimumab appropriate quadrant location dominated. Combination therapies: etanercept + MTX NE quadrant, US$7925. Adalimumab + MTX and infliximab + MTX dominated Statistical analysis for Not undertaken patient-level stochastic data Appropriateness of statistical NA analysis Uncertainty around Not undertaken cost-effectiveness expressed Appropriateness of method NA dealing with uncertainty around cost effectiveness Sensitivity analysis Yes: one-way sensitivity analyses were performed on all input variables. Cost variables were varied from 50 to 200% of baseline and probability values increased and decreased by 50% of baseline. Cost of treatment and the probability of achieving ACR response criteria were the main drivers of ICERs. Costs of SAEs, probabilities of developing SAEs, healthcare resource costs and the cost of MTX did not affect the ICERs Modelling inputs and Yes techniques appropriate Authors’ conclusions Anakinra was the least expensive option and etanercept dominated other treatments. Cost of drugs and probability for achieving response were the main drivers of ICERs TABLE 85 Bansback et al., 2005 166 Authors Bansback, Brennan, Ghatnekar Date 2005 Type of economic evaluation Cost–utility analysis Country of origin UK, Sweden Currency used Euros Year to which costs apply 2001 Perspective Healthcare Study population Patients with moderate to severe RA for whom at least two traditional DMARDs had failed (simulation of 10,000 patients) Intervention 1 Adalimumab monotherapy Intervention 2 Adalimumab + MTX (study nos DE009 and DE019) Intervention 3 Adalimumab + MTX (study no. DE009) Intervention 4 Etanercept monotherapy Intervention 5 Etanercept + MTX Intervention 6 Infliximab + MTX continued
TABLE 85 Bansback et al., 2005 166 (cont’d) © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Intervention 7 Traditional drug treatment (DMARDs) Source of effectiveness data Treatment response data from a published review and conference abstracts. Two combination RCTs were available for adalimumab. The first, ARMADA, was similar to the etanercept and infliximab trials in design and patient numbers. The second, a larger, more comprehensive study, also included radiographic evaluations. In Sweden, decisions to continue treatment are made using the DAS response criteria. This study presents results for two definitions of classifying successful response: ACR20 and ACR50. Comparison of trials suggests similarities between the results of ACR and DAS responses. This model assumes that ACR20 corresponds to a moderate DAS28 score and ACR50 corresponds to a good DAS score. In addition, HAQ was mapped to a health utility measure (HUI 3). Analysis of patient-level adalimumab data was used to calculate HAQ improvement in ACR20 and ACR50 responders. The model assumed that HAQ worsened after withdrawal from treatment, immediately at the point of withdrawal and equalled the initial HAQ improvement for all treatments Cost data handled Yes appropriately Modelling summary A decision-analytic model building on two previously described models. Patient-based transition state model, simulating a population of 10,000 patients. A cycle length of 6 months was used, within which the risks of withdrawal, adverse events and mortality were determined, based on experiences of an average patient. Patients were simulated for their lifetime. Model parameter values were derived from patient-level data analysis of adalimumab RCTs or published sources Outcome measures used in At each 6-month cycle in the model the patients’ health-related quality of life scores were economic evaluations evaluated by simple linear transformation from the HAQ-DI score. From this a cost–utility analysis was possible Direction of result with NE quadrant appropriate quadrant location For the group ACR50/DAS28 good: €34,167 per QALY (adalimumab + MTX) €34,922 per QALY (adalimumab + MTX) a €35,760 per QALY (etanercept + MTX) €48,333 per QALY (infliximab + MTX) €41,561 per QALY (adalimumab) €36,927 per QALY (etanercept) For the group ACR20/DAS28 moderate: €40,875 per QALY (adalimumab + MTX) €44,018 per QALY (adalimumab + MTX) a €51,976 per QALY (etanercept + MTX) €64,935 per QALY (infliximab + MTX) €65,499 per QALY (adalimumab) €42,480 per QALY (etanercept) Statistical analysis for Patient-level data were used to calculate HAQ improvement in patients who were ACR20 patient-level stochastic data and ACR50 responders Appropriateness of statistical Yes analysis Uncertainty around Yes. Cost-effectiveness acceptability curve and cost-effectiveness plane cost-effectiveness expressed Appropriateness of method Yes. Appropriate methods were used: both central values and probability density functions dealing with uncertainty were used to describe the distribution of uncertainty around cost effectiveness Sensitivity analysis Yes. Univariate sensitivity analysis and multivariate sensitivity analysis were used. Uncertainty in assumptions around model structure was also explored Modelling inputs and Yes techniques appropriate Authors’ conclusions Adalimumab appears to be cost-effective for the treatment of moderate to severe RA. Results suggest that adalimumab is at least as cost-effective as other TNF inhibitors, with the exception of infliximab; the cost results were between €35,000 and €42,000 per QALY, a range normally considered cost-effective in European countries a Including additional information from a larger adalimumab trial in a pooled analysis. 171
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
Page 129:
The substantial economic impact of
Page 133 and 134:
Summary Effectiveness: principal fi
Page 135 and 136: inhibitors, although the incrementa
Page 137 and 138: introduce bias which generally exag
Page 139: Adalimumab, etanercept and inflixim
Page 143 and 144: 1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146: 46. Young A, Dixey J, Cox N, Davies
Page 147 and 148: tumor necrosis factor therapy in th
Page 149 and 150: arthritis: a 12-week, double-blind,
Page 151 and 152: 171. Geborek P, Crnkic M, Petersson
Page 153 and 154: 216. Schotte H, Willeke P, Mickholz
Page 155 and 156: The Health Assessment Questionnaire
Page 157 and 158: Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160: Appendix 3 © Queen’s Printer and
Page 161: TABLE 69 Studies excluded from clin
Page 164 and 165: 148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167: 150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169: 152 Appendix 4 Infliximab versus pl
Page 170 and 171: 154 Appendix 4 Infliximab plus MTX
Page 173: Ovid MEDLINE(R) 1966 to February we
Page 177 and 178: Appendix 8 © Queen’s Printer and
Page 179 and 180: TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182: TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184: TABLE 82 Brennan et al., 2004 160
Page 185: TABLE 83 Kobelt et al., 2004 163 (c
Page 189: TABLE 86 Kobelt et al., 2005 167 (c
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 221 and 222: TABLE 132 Variation 10: TNF inhibit
Page 237 and 238:
TABLE 156 Variation 16: TNF inhibit
Page 239 and 240:
Page 241 and 242:
Page 243:
Page 247 and 248:
Volume 1, 1997 No. 1 Home parentera
Page 249 and 250:
No. 3 Screening for sickle cell dis
Page 251 and 252:
No. 25 A rapid and systematic revie
Page 253 and 254:
No. 11 First and second trimester a
Page 255 and 256:
No. 23 Clinical effectiveness and c
Page 257 and 258:
No. 28 Outcomes of electrically sti
Page 259:
No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263:
246 Health Technology Assessment Pr
Page 264:
248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?